http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8906134-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af6eb5bf72b8f7eac76ac4e5bc2811bf
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06104
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06
filingDate 1988-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5f7caf4c46702fd151bab1341af9c1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba6f610c3a92ca02bc83103816e14bde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8873f2db5d0892378456666de7ef30e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15226d53297147ccefc626339953b9c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c09ac2b08fec31dcb5194664cc0ee7a4
publicationDate 1989-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-8906134-A1
titleOfInvention Pharmaceutical preparation for treating immunodeficiency conditions
abstract A pharmaceutical preparation for treating immunodeficiency conditions consists of an active substance-peptide having the structure H-L-Glu-L-$g(t)rp-OH, and of a pharmaceutical diluent.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9640740-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6066622-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5811399-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5807830-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6096713-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5770576-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/LT-4476-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6346514-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/LT-4393-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6368788-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6159940-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6777195-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6911431-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1840133-A1
priorityDate 1987-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4699898-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SU-1277903-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4751216-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0240033-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID4236
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID4236
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID37490
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID6550
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID6550
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID37490
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID29109
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559524

Total number of triples: 57.